What is Pharming Group N.V.'s current stock price?

As of the latest data, Pharming Group N.V. is trading at €1.37 on the Euronext exchange. For more details, visit their Meyka page here .

How does Pharming Group N.V. rank in its sector?

Pharming is a key player in the biotechnology industry, with strategic collaborations contributing to its market presence, despite current profitability challenges.

What is Pharming Group's EPS and PE ratio?

Pharming's EPS is -€0.01, and it has a negative PE ratio of -136.7, reflecting current challenges in achieving positive earnings results compared to its market valuation.

What are the risks and opportunities for Pharming Group N.V.?

Risks include financial volatility and high operational costs, while opportunities lie in sector growth and strategic partnerships that could drive future success.

Who are Pharming Group's strategic partners?

Pharming has entered into strategic agreements with Novartis and Orchard Therapeutics, focusing on innovative therapies and potential expansion in various markets.

EU Stocks

Pharming Group N.V. (PHARM.AS) Stock Analysis: Navigating Market Volatility and Strategic Partnerships

ByHuzaifa Zahoor December 4, 2025December 4, 2025

Pharming Group N.V. (PHARM.AS) is making moves on the Euronext exchange, with its stock currently priced at €1.37. As a prominent player in the biopharmaceutical sector, known for its innovative therapies, the company’s strategic partnerships and market performance merit a closer look.